KEGG   NETWORK: N00025Help
Entry
N00025                      Network                                

Name
EML4-ALK fusion kinase to PLCG-ERK signaling pathway
Definition
EML4-ALK -> PLCG -> (Ca2+,DAG) -> PKC -> RAF -> MEK -> ERK -> CCND1
  Expanded
(238v1,238v2) -> (5335,5336) -> (C00076,C00165) -> (5578,5579,5582) -> (369,673,5894) -> (5604,5605) -> (5594,5595) -> 595
Class
nt06210 ERK signaling
nt06266 Non-small cell lung cancer
Type
Variant
Pathway
hsa05223  Non-small cell lung cancer
Disease
H00014  Non-small cell lung cancer
Gene
238  ALK; ALK receptor tyrosine kinase
5335  PLCG1; phospholipase C gamma 1
5336  PLCG2; phospholipase C gamma 2
5578  PRKCA; protein kinase C alpha
5579  PRKCB; protein kinase C beta
5582  PRKCG; protein kinase C gamma
369  ARAF; A-Raf proto-oncogene, serine/threonine kinase
673  BRAF; B-Raf proto-oncogene, serine/threonine kinase
5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase
5604  MAP2K1; mitogen-activated protein kinase kinase 1
5605  MAP2K2; mitogen-activated protein kinase kinase 2
5594  MAPK1; mitogen-activated protein kinase 1
5595  MAPK3; mitogen-activated protein kinase 3
595  CCND1; cyclin D1
Variant
238v1  EML4-ALK fusion
238v2  First generation TKI-resistant ALK1 mutation
Reference
  Authors
Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr
  Title
Role of HGF/MET axis in resistance of lung cancer to contemporary management.
  Journal
Transl Lung Cancer Res 1:179-93 (2012)
DOI:10.3978/j.issn.2218-6751.2012.09.04
Reference
  Authors
Roskoski R Jr
  Title
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
  Journal
Pharmacol Res 68:68-94 (2013)
DOI:10.1016/j.phrs.2012.11.007

DBGET integrated database retrieval system